Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: A systematic review

Cancer Treatment Reviews

Volumn 39, Issue 6, 2013, Pages 610-621

  Verbrugghe, M ^a   Verhaeghe, S ^a   Lauwaert, K ^a   Beeckman, D ^a,b,c   Van Hecke, A ^a,d  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY COLLEGE GHENT   (Belgium)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Associated factors; Determinants; Non adherence; Non persistence; Oncology; Oral anticancer drugs

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CHRONIC MYELOID LEUKEMIA; HEALTH CARE SYSTEM; HUMAN; MASTECTOMY; PATIENT COMPLIANCE; PRESCRIPTION; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; HUMANS; MEDICATION ADHERENCE; NEOPLASMS;

EID: 84878948028     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.12.014     Document Type: Review

References (73)

1. Banna L.G., Collovà E., Gebbia V., Lipari H., Giuffrida P., Cavallaro S., et al. Anticancer oral therapy: emerging related issues. Cancer Treat Rev 2010, 69:595-605.
2. Foulon V., Schöffski P., Wolter P. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg 2011, 66(2):85-96.
3. Eliasson L., Clifford S., Barber N., Marin D. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 2011, 35:626-630.
4. Regnier Denois V., Poirson J., Nourissat A., Jacquin J.-P., Guastalla J.P., Chauvin F. Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists. Eur J Cancer Care 2010, 20:520-527.
5. Fallowfield L., Atkins L., Catt S., Cox A., Coxon C., Langridge C., et al. Patients' preferences for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 2006, 17:205-210.
6. Wojtacki J., Wiraszka R., Rolka-Stempniewicz G., et al. Breast cancer patients' preferences for oral versus intravenous second-line anticancer therapy. Eur J Cancer 2006, 159:abstr 381.
7. Paley M., Love N., Carlson R., et al. Preferences for oral, parenteral antitumor therapy: a survey of 260 patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2005, 23:619.
8. Liu G., Franssen E., Fitch M.I., Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997, 15:110-115.
9. Simchowitz B., Shiman L., Spencer J., Brouillard D., Gross A., Connor M., et al. Perceptions and experiences of patients receiving oral chemotherapy. Clin J Oncol Nurs 2010, 14(4):447-453.
10. Gebbia V., Bellavia G., Ferraù F., Valerio M.R. Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents. Expert Opin Drug Saf 2011, 11(S1):S49-S59.
11. Ruddy K., Mayer E., Partridge A. Patient adherence and persistence with oral anticancer treatment. CA: Cancer J Clin 2009, 59(1):56-66.
12. Partridge A.H., Avorn J., Wang P.S., Winer E.P. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002, 94(9):652-661.
13. Cramer J.A., Roy A., Burrell A., Fairchild C.J., Fuldeore M.H., Ollendorf D.A., et al. Medication compliance and persistence. Terminology and definitions. Value Health 2008, 11(1):44-47.
14. Sedjo R.L., Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 2011, 125(1):191-200.
15. Fink A.K., Gurwitz J., Rakowski W., Guadagnoli E., Silliman R.A. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 2004, 22(16):3309-3315.
16. Lash T.L., Fox M.P., Westrup J.L., Fink A.K., Silliman R.A. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 2006, 99(2):215-220.
17. Noens L., van Lierde M.-A., De Bock R., Verhoef G., Zachée P., Berneman Z., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113(22):5401-5411.
18. Ganesan P., Sagar T.G., Dubashi B., Rajendranath R., Kannan K., Cyriac S., et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 2011, 86(6):471-474.
19. Ibrahim A.R., Eliasson L., Apperley J.F., Milojkovic D., Bua M., Szydlo R., et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011, 117(14):3733-3736.
20. Marin D., Bazeos A., Mahon F.X., Eliasson L., Milojkovic D., Bua M., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28(14):2381-2388.
21. McCowan C., Shearer J., Donnan P.T., Dewar J.A., Crilly M., Thompson A.M., et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008, 99(11):1763-1768.
22. Wu E.Q., Guerin A., Yu A.P., Bollue V.K., Guo A., Griffin J.D. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukaemia. Curr Med Res Opin 2010, 26(12):2861-2869.
23. Darkow T., Henk H.J., Thomas S.K., Feng W., Baladi J.-F., Goldberg G.A., et al. Treatment interruption and non-adherence with imatinib and associated healthcare costs - a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007, 25(6):481-496.
24. World Health Organization Adherence to long-term therapies, evidence for action 2003, Geneva.
25. Van Meijel B., Gamel C., Swieten-Duijfjes B., Grypdonck M.H. The development of evidence-based nursing interventions: methodological considerations. J Adv Nurs 2004, 48:84-92.
26. Moore S. Nonadherence in patients with breast cancer receiving oral therapies. Clin J Oncol Nurs 2010, 14(1):41-47.
27. Vyncke V, De Clercq B, Stevens V, Costongs C, Barbareschi G, Hrafn Jónsson S, et al. Does neighborhood social capital aid in leveling the social gradient in the health and well-being of children and adolescents? A literature review. BMC Public Health 2013;13(65):in press.
28. Public Health Resource Unit (2006) Critical appraisal skills programme (CASP) making sense of evidence, 10 questions to help make sense of qualitative research. Retrieved from: 16 April 2012. http://www.sph.nhs.uk/sph-files/casp-appraisal-tools/Qualitative%20Appraisal%20Tool.pdf.
29. Thomas B.H., Ciliska D., Dobbins M., Micucci S. A process for systematically reviewing the literature: providing the research evidence for public health nursing interventions. Worldviews Evid Based Nurs 2004, 1(3):176-184.
30. Mirza M., Fitzpatrick-Lewis D., Thomas H. Is there a relationship between food insecurity and overweight/obesity? Hamilton, ON: Ontario public health research 2007, Effective Public Health Practice Project, Education and Development.
31. Lebovits A.H., Strain J.J., Schleifer S.J., Tanaka J.S., Bhardway S., Messe M.R. Patient noncompliance with self-administered chemotherapy. Cancer 1990, 65:17-22.
32. Kirk M.C., Hudis C.A. Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 2008, 8(2):155-161.
33. Güth U., Huang D.J., Schötzau A., Zanetti-Dällenbach R., Holzgreve W., Bitzer J., et al. Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br J Cancer 2008, 99:428-433.
34. Partridge A.H., Wang P.S., Winer E.P., Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003, 21(4):602-606.
35. Partridge A.H., Archer L., Kornblith A.B., Gralow J., Grenier D., Perez E., et al. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol 2010, 28(14):2418-2422.
36. Grunfeld E.A., Hunter M.S., Sikka P., Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 2005, 59:97-102.
37. Hershman D.L., Kushi L.H., Sha T., Buono D., Kershenbaum A., Tsai W.-Y., et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8769 early-stage breast cancer patients. J Clin Oncol 2010, 28(27):4120-4128.
38. Kimmick G., Anderson R., Camacho F., Bhosle M., Hwang W., Balkrishnan R. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 2009, 27(21):3445-3451.
39. Nekhlyudov L., Li L., Ross-Degnan D., Wagner A.K. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 2011, 130:589-681.
40. Neugut A.I., Subar M., Wilde E.T., Stratton S., Brouse C.H., Hillyer G.C., et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 2011, 29(18):2534-2542.
41. Marques P.A.C., Pierin A.M.G. Factors that affect cancer patient compliance to oral anti-neoplastic therapy. Acta Paulista de Enfermagem 2008, 21(2):323-329.
42. Owusu C., Buist D.S.M., Field T.S., Lash T.L., Thwin S.S., Geiger A.M., et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. Am Soc Clin Oncol 2008, 26(4):549-555.
43. Barron T.I., Connolly R.M., Bennett K., Feely J., Kennedy J.M. Early discontinuation of tamoxifen. Am Cancer Soc 2007, 109(5):832-839.
44. Ma A.M.T., Barone J., Wallis A.E., Wu N.J., Garcia L.B., Estabrook A., et al. Noncompliance with adjuvant radiation, chemotherapy or hormonal therapy in breast cancer patients. Am J Surg 2008, 196:500-504.
45. Streeter S.B., Schwartzberg L., Husain N., Johnsrud M. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract 2011, 7(3S):46s-51s.
46. Kahn K.L., Schneider E.C., Malin J.L., Adams J.L., Epstein A.M. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 2007, 45(5):431-439.
47. Demissie S., Silliman R.A., Lash T.L. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001, 19(2):322-328.
48. Atkins L., Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 2006, 42:2271-2276.
49. Mann C.J. Observational research methods. Research design II: cohort, cross-sectional, and case-control studies. Emerg Med J 2003, 20:54-60.
50. Black N. Why we need qualitative research. J Epidemiol Community Health 1994, 48:425-426.
51. Stavropoulou C. Non-adherence to medication and doctor-patient relationship: evidence from a European survey. Patient Educ Couns 2011, 83:7-13.
52. Van Hecke A., Verhaeghe S., Grypdonck M., Beele H., Defloor T. Processes underlying adherence to leg ulcer treatment: a qualitative field study. Int J Nurs Stud 2011, 48(2):145-155.
53. Vervoort S., Borleffs J., Hoepelman A., Grypdonck M. Adherence in antiretroviral therapy: a review of qualitative studies. AIDS 2007, 21:271-281.
54. Gebia V., Bellavia G., Ferraù F., Valerio M.R. Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents. Expert Opin Drug Saf 2012, 11(1):S49-S59.
55. Hess L.M., Raebel M.A., Conner D.A., et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006, 40:1280-1288.
56. Simpson S.H., Eurich D.T., Majumdar S.R., et al. A meta-analysis of the association between adherence to drug therapy and mortality. Br Med J 2006, 333:15-20.
57. Sikka R., Xia F., Aubert R.E. Estimating medication persistency using administrative claims data. Am J Manag Care 2005, 11:449-457.
58. Arnsten J.H., Demas P.A., Farzadegan H., Grant R.W., Gourevitch M.N., Chang C.-J., et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. HIV/AIDS 2001, 33:1417-1423.
59. Shi L., Liu J., Fonseca V., Walker P., Kalsekar A., Pawaskar M. Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis. Health Qual Life Outcomes 2010, 8(99).
60. Gysels M., Higginson I.J. Interactive technologies and videotapes for patient education in cancer care: systematic review and meta-analysis of randomized trials. Support Cancer Care 2007, 15:7-20.
61. McPherson C.J., Higginson I.J., Hearn J. Effective methods of giving information in cancer: a systematic review of randomized controlled trials. J Public Health Med 2001, 23:227-234.
62. Moore S. Facilitating oral chemotherapy treatment and compliance through patient/family-focused education. Cancer Nurs 2007, 30:112-122.
63. Hartigan K. Patient education: the cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nurs 2003, 7:21-24.
64. Vermeire E., Hearnshaw H., Van Royen P., Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001, 26:331-342.
65. Kav S., Johnson J., Rittenber C., Fernadez-Ortega P., Suominen T., Olsen P.R., et al. Role of the nurse in patient education and follow-up of people receiving oral chemotherapy treatment: an international survey. Support Care Cancer 2008, 16:1075-1083.
66. Wenzel L., Fairclough D., Brady M., et al. Age-related differences in the quality of life of breast carcinoma patients after treatment. Cancer 1999, 86:1768-1774.
67. Ganz P. Breast cancer in older women: quality-of-life considerations. Cancer Control 1994, 1:372-379.
68. Compas B., Stoll M., Thomsen A., et al. Adjustment to breast cancer: age-related differences in coping and emotional distress. Breast Cancer Res Treat 1999, 54:195-203.
69. Petrek J., Naughton M. Case, et al. Incidence, time course, and determinates of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006, 24:1045-1051.
70. Chia L.R., Schlenk E.A., Dunbar-Jacob J. Effect of personal and cultural beliefs on medication adherence in the elderly. Drugs Aging 2006, 23:191-202.
71. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther 1998, 20:764-771.
72. Boyd E.A., Cho M.K., Bero L.A. Financial conflict-of-interest policies in clinical research: issues for clinical investigators. Acad Med 2003, 78(8):769-774.
73. McPherson C.J., Higginson I.J., Hearn J. Effective methods of giving information in cancer: a systematic literature review of randomized controlled trials. J Public Health Med 2001, 23(3):227-234.